Kornimate/medical-research-clean huggingface dataset:
transthoracic sonography versus high resolution computed tomography in alveolar intersitial syndrome

Conditions: Pleural Diseases

Summary: high resolution computed tomography of the chest is the gold standard imaging modality for most pulmonary diseases. however, the associated high expenses, radiation exposure , and its limited possibility for bedside use are a limitation.

high resolution computed tomography of the chest is the gold standard imaging modality for most pulmonary diseases. however, the associated high expenses, radiation exposure , and its limited possibility for bedside use are a limitation. transthoracic ultrasonograghy is used progressively for evaluation of pulmonary diseases. its non invasive nature , relatively low price ,portability for bedside use, and high reproducibility of results allows for incorporation of imaging findings with clinical data. although transthoracic ultrasonograghy is not an alternative to high resolution computed tomography,it can potentially provide useful supplemental information in certain specific situations ,such as for rapid bedside diagnostic assessment of dyspneic patients. b-line is a common and significant abnormal sign used for diagnostic appraisal by transthoracic ultrasonograghy, but it cannot define the exact underlying pathologic feature on a lung ultrasound. when the lung parenchymal pathology reaches the lung surface ,certain characteristic changes of the pleural line can be detected by means of the good imaging made possible by high-resolution transthoracic ultrasonograghy ,but the application and strength of pleural line abnormalities in the differential diagnosis of lung diseases has not been adequately explored . existing literature on the illustration of the pleural line is scarce ,and the shape of pleural line has not been adequately investigated and described ,especially in comparison with computed tomography findings. most studies that have investigated pleural lines are confined to the sub population with interstitial lung diseases.

Eligibility criteria:
inclusion criteria: 1. patients presenting with dyspnea due to interstitial fibrosis syndrome. 2. pulmonary edema due to any cause. exclusion criteria: 1. traumatic lesions 2. pneumothorax 3. subcutaneous emphysema 4. massive pleural effusion with atelectasis, and
a long-term study of mp-214 in patients with receiving multiple drugs schizophrenia

Conditions: Schizophrenia

Summary: the objective of this study is to evaluate the long-term safety, tolerability, and efficacy of mp-214 in patients with receiving multiple drugs schizophrenia.


Eligibility criteria:
inclusion criteria: * written informed consent obtained from the patient before the initiation of any study-specific procedures * patients diagnosed with schizophrenia according to the diagnostic criteria of the diagnostic and statistical manual of mental disorders, fourth edition, text revision (dsm-iv-tr) criteria for schizophrenia * patients who receive 1 or more antipsychotic drugs * patients with normal physical examination, laboratory, vital signs, and/or electrocardiogram (ecg) exclusion criteria: * patients with a dsm-iv-tr diagnosis of schizoaffective disorder, schizophreniform disorder, other psychotic disorders other than schizophrenia, or bipolar i or ii disorder the information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Keywords: schizophrenia antipsychotic agents mental disorder psychotropic drugs dopamine agents central nervous system agents
atomoxetine to treat korean children and adolescents with attention-deficit/hyperactivity disorder (adhd)

Conditions: Attention Deficit Hyperactivity Disorder

Summary: the purpose of this study is to provide information regarding the relative effectiveness of three different atomoxetine doses in the treatment of korean children and adolescents with attention-deficit/hyperactivity disorder (adhd)


Eligibility criteria:
inclusion criteria: * patients will be outpatients who are aged 6 to 18 years old at the initial screening visit. * patients must have adhd, based on the accepted criteria for that disease * patients must not have taken any medication used to treat adhd for at least two weeks prior to beginning study treatment; and at least one week prior to the study screening visit during which initial adhd assessments were made * patients must be able to swallow capsules * patients and parents (or legal guardians) must be judged by the study investigator to be reliable to keep appointments for clinic visits and all tests, including blood tests and any other required examinations exclusion criteria: * patients must not have received any treatment within the last 30 days with a drug that has not been approved by their country's appropriate government agency * patients will not be included in the study if they have previously experienced any unwanted effects or serious medical events during atomoxetine treatment * patients will not be included in the study if they are judged by the study investigator to be at serious suicidal risk * patients will not be included in the study if they have cardiovascular disease or other conditions that could be worsened by an increased heart rate or increased blood pressure
tac, mini-mtx, mmf versus tac, mtx for gvhd prevention

Conditions: Chronic Myelogenous Leukemia; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Acute Biphenotypic Leukemia; Myelodysplastic Syndrome; Myeloproliferative Neoplasm; Non-Hodgkin Lymphoma; Hodgkins Disease; Chronic Lymphocytic Leukemia; Multiple Myeloma

Summary: this randomized clinical trial studies standard gvhd prophylaxis with tacrolimus and methotrexate compared to tacrolimus, mycophenolate mofetil and a reduced-dose methotrexate in patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplant. both mycophenolate mofetil and reduced-dose methotrexate, in combination with a calcineurin inhibitor, have been shown to be safe and effective in gvhd prevention with less toxicity than standard dose methotrexate. it is not yet known, however, whether this combination of mycophenolate mofetil and reduced-dose methotrexate with tacrolimus is more effective than tacrolimus and standard dose methotrexate in preventing gvhd.

study design this is a prospective randomized trial to determine the effectiveness of different doses of gvhd prophylaxis on mucositis, engraftment and agvhd. study consists of two study groups of 50 subjects each. group a will receive tac and mtx (15 mg/m2 day +1, 10 mg/m2 day +3, +6, +11). group b will receive tac, mini-dose mtx (5 mg/m2 on day +1, +3, +6) and mmf.

Eligibility criteria:
inclusion criteria: * patients must have one of the following documented diseases: * chronic myelogenous leukemia * chronic lymphocytic leukemia * multiple myeloma * myelodysplasia * myeloproliferative disorder * non-hodgkin's lymphoma * hodgkin's disease * acute myelogenous leukemia * acute lymphoblastic leukemia * acute biphenotypic leukemia * patients must be undergoing a myeloablative allogeneic hematopoietic cell transplant with one of the following conditioning regimens: * busulfan (≥ 12.8 mg/kg iv or po) and cyclophosphamide (≥ 120 mg/kg) --- busulfan dose may be adjusted according to pharmacokinetics targeting a daily auc of 5000 μmol-min/l, per institution standard of practice. * total body irradiation (tbi) (≥ 1200 cgy) and etoposide (60 mg/kg) * tbi (≥ 1200 cgy) and cyclophosphamide (120 mg/kg) * patient must have achieved and be in complete morphologic remission prior to starting conditioning regimen * patient's donor must be a related or unrelated human leukocyte antigen (hla) 8/8 allele-level match (hla-a, b, c and drb1) * adult patients must have an eastern cooperative oncology group (ecog) performance status of 0 or 1; pediatric patients must have lansky score ≥ 60% * patients must have a life expectancy of 100 days * patients must sign written informed consent exclusion criteria: * patients who have undergone any prior transplant * patients who are seropositive for human immunodeficiency virus (hiv) * patients with any medical illness or concurrent psychiatric illness which, in the investigators' opinion, cannot be adequately controlled with appropriate therapy * patients who are pregnant or lactating
hybrid intelligence for trustable diagnosis and patient management of prostate cancer (hit-pirads)

Conditions: Prostate Cancer

Summary: the purpose of this study is to develop a new way to diagnose prostate cancer through the use of artificial intelligence. the goal is for this new method to reduce delays in diagnoses and to avoid invasive procedures such as biopsies.

the overall goal of this project is to create a diagnosis and patient management strategy (called hit-pirads) for prostate cancer (pca) that will significantly increase positive predictive value (ppv) for clinically significant pca detection while minimizing unnecessary prostate biopsies and related morbidities. due to its interpretable nature and bias correction paradigm, the ai system will generate predictions that physicians can trust. one of the immediate outcomes of the system will be a reproducible risk scoring system that can be used in community hospitals and locales without mri-subspeciality genitourinary trained radiologists to improve the accuracy of prostate imaging nationwide. in the long term, the investigators expect hit-pirads to be widely adopted in clinics and trigger other treatment and prevention strategies to be developed based on hit-pirads.

Eligibility criteria:
inclusion criteria: * elevated psa (4.0-10.0 ng/ml) or abnormal digital rectal exam with psa of 2.00-10.00 ng/ml as indicated in the patient's lab report. * patients must be biopsy naïve, confirmed with patient or medical record. * patients must be male, ≥18 and ≤ 89 years of age. * patient must have a life expectancy ≥10 years, determined by pi. * patients must exhibit an ecog performance status of 0-2, as noted in their medical record. exclusion criteria: * patients who are on a 5-α-reductase inhibitor within 12 months of enrollment, as confirmed by medical record. * patients who have had a prostate infection within 1 month of enrollment, as confirmed by medical record. * patients who are receiving or who received prostate cancer treatment (e.g., androgen deprivation therapy, surgery, radiation therapy or adjuvant/neoadjuvant therapy with investigational drugs) per their medical record. * patients who've had an invasive urological procedure within 1 month of enrollment, as confirmed by their medical record and patient reporting. * patients with no access to the rectum for a transrectal ultrasound, as determined by the urologist. * patients with a contraindication to magnetic resonance imaging (mri). * vulnerable populations: prisoners or adult men \>89 years old.

Keywords: elevated psa elevated prostate-specific antigen abnormal digital rectal exam prostate cancer prostate ai artificial intelligence oncology
probiotic supplementation during pregnancy in preeclampsia high-risk groups

Conditions: PE (Pre-eclampsia) High-risk Population With Gut Microbiota Dysbiosis During Their Pregnancy

Summary: in this randomized controlled study, preventive intervention of aspirin combined with probiotics or aspirin combined with placebo would given to pe (pre-eclampsia) high-risk population with gut microbiota dysbiosis during their pregnancy, and finally assess the efficacy and safety of aspirin combined with probiotics to prevent pe.


Eligibility criteria:
inclusion criteria: * pe high-risk population aged 18-50 years with gut microbiota dysbiosis * no severe cardiopulmonary diseases * no severe hepatic and renal insufficiency * no severe active infection * pregnant women did not take antibiotics or antifungal drugs 30 days before fecal sample collection; no probiotic preparation was taken 2 weeks before sample collection; never take drugs that may interfere with glucose and lipid metabolism * no diseases affecting intestinal microecology * no history of smoking and drinking * the researchers evaluated those pregnant women expected to deliver more than 20 weeks * voluntarily participate in this clinical study and sign the informed consent form exclusion criteria: * with severe cardiopulmonary, hepatic and renal insufficiency * with uncontrolled active infections 2 weeks before enrollment * subjects took antibiotics or antifungal drugs 30 days before sample collection; take probiotics 2 weeks before sample collection; have taken drugs that may interfere with glucose and lipid metabolism * with diseases affecting intestinal microecology * smoking and drinking history * with acute gastrointestinal ulcer * hemorrhagic constitution * other discomfort assessed by the investigato
impact of protein supplementation to mother milk on resting energy expenditure (ree) in growing healthy preterm infants.

Conditions: Infant,Premature

Summary: resting energy expenditure is the amount of energy, usually expressed in kcal required for a 24 hour period by the body during resting conditions. it is closely related to, but not identical to, basal metabolic rate. according to the espghan committee guidelines on enteral nutrient supply for preterm infants, which were published in 2010, the daily protein intake of extremely low birth weight infants shall be 4.5 g/kg/day, and for those above 1000g, 4 g/kg/day. in order to meet these recommendations, the human milk for all premature infants is enriched with human milk fortifier, and supplemental liquid protein according to our nicu protocol. little is known on the effect of this enrichment on the basal metabolic rate of premature infants. one way of determining the basal metabolic rate is by measuring the resting energy expenditure. in order to do that the investigators use an indirect calorimety by using the deltatrac ii metabolic monitor (datex-ohmeda). this instrument uses the principle of the open-circuit system that allows continuous measurements of oxygen consumption and carbon dioxide production using a constant flow generator.

infants will be enrolled when tolerating full feeds (150-160 ml/kg/d) of human breast milk fortified with standard fortifier for 2 days and before protein supplementation. metabolic studies will be conducted while the infants are prone and asleep and at the same time of the day (noon time) for all infants, starting 1 hour after the completion of the last feed. measurements will be stopped during body movements. each measure, once a day, will last for 30 min. a total of 4 ree measurements will be performed for all participants: before starting with protein supplementation, on day 0 (d0), and at days 2, 3 and 4 of protein supplementation.

Eligibility criteria:
inclusion criteria: * preterm infants born with birth weight \< 1500 g gestation * full enteral feeds (150-160 ml/kg/d) of breast milk fortified with standard hm fortifier will be well tolerated for 2 days, without significantly gastric residuals (less than 5%) * clinically and thermally stable. exclusion criteria: * ventilated infant (invasive or non-invasive) * necrotizing enterocolitis (nec) * ivh grade 3-4 * bpd * pda * active infection. * congenital or genetic disorder ( trisomy, heart defect.)
rehabilitation treatment of anterior cruciate ligament rupture

Conditions: ACL Injury

Summary: the purpose with this present study is to investigate the effect og a non-surgical regime in patients with an anterior cruciate ligament injury. the effect will be measured by patient reported outcome scores, level of function and how many of the patients are converting to operative treatment.


Eligibility criteria:
inclusion criteria: * anterior cruciate ligament injury where rehabilitation regime is selected as treatment. exclusion criteria: * other knee ligament instability * rheumatoid arthritis * morbus bechterews disease
value of diffusion weighted magnetic resonance imaging in detection of recurrent disease in surgically treated cervical and endometrial cancer patients

Conditions: Cervical Cancer; Endometrial Cancer

Summary: endometrial and cervical cancers are one of the most common malignancies seen in females. identification of recurrent disease in early phases of treatment carries a primary importance on the outcome of patients. diffusion-weighted magnetic resonance imaging (dwi) is a new technique recently started to be performed in body imaging and has potential ability to detect recurrent disease. the aim of this study is to investigate the diagnostic impact of dwi in detection of recurrent disease in patients treated with curative surgery in endometrial and cervical cancer.

endometrial and cervical cancers are one of the most common malignancies seen in female genital tract. although, surgical resection is the treatment of choice for both, adjuvant or neo-adjuvant chemotherapy or radiotherapy and curative radiotherapy are alternative treatment options depending on the stage. identification of recurrent disease in early phases carries a primary importance on the prognosis. diffusion-weighted mri (dwi), a new technique recently started to be performed in body imaging has potential ability to distinguish recurrent disease from normal tissue or fibrosis. our aim in this study is to investigate the diagnostic impact of dwi in detection of recurrence rate in patients treated with curative surgery in endometrial and cervical cancer. all patients who had curative surgery due to endometrial or cervical cancer will be included to the study. patients will be examined with dwi in addition to routine sequences including contrast enhanced dynamic studies. the sensitivity, specificity, accuracy as well as positive and negative predictive values of the study will be investigated from the data derived from dwi studies and will be correlated with data obtained by conventional radiologic, nuclear imaging studies including pet-ct, as well as pathologic verifications during follow-up period.

Eligibility criteria:
inclusion criteria: * pathologic diagnosis of cervical or endometrial cancer. * patients treated with curative surgery (hysterectomy)will be involved on a voluntary basis. exclusion criteria: * contraindications for mri examination (cardiac pacemakers, metallic objects, cochlear implants, claustrophobic patients)

Keywords: diffusion weighted mri curative surgery recurrence
post marketing surveillance of nintedanib in indian patients with non-small cell lung cancer (nsclc) after first-line therapy

Conditions: Non-small Cell Lung Cancer

Summary: this active surveillance aims to collect the safety data of 100 nsclc patients treated with nintedanib per the approved indian label within 2 years from the date of commercial availability of the drug in india (23rd january 2017). the objective is to look at the safety of nintedanib in the real world setting.


Eligibility criteria:
inclusion criteria: * patients ≥18 years of age with locally advanced and/or metastatic nsclc of stage iiib or iv, or recurrent nsclc and adenocarcinoma histology after first line chemotherapy who have initiated or will initiate nintedanib \& docetaxel according to the package insert after the commercial availability of drug in india (23rd january 2017). * patients in whom it is possible to obtain voluntary informed consent from either the patient or patient's legally authorised representative (applicable for group b and c patients). * patients in whom data collection is possible from the medical records (applicable for group a and b patients). * further inclusion criteria apply. exclusion criteria: * patients who were previously treated with nintedanib. * patients who are positive for endothelial growth factor receptor (egfr) mutations or anaplastic lymphoma kinase (alk) rearrangements * patients who are participating in a clinical trial. * further exclusion criteria apply.
biomarkers in ev associated with marrow adiposity in anorexia

Conditions: Anorexia Nervosa Restricting Type; Anorexia Nervosa (DSM-IV Revised Criteria)

Summary: the aim of this observational study is to identify biomarkers in extracellular vesicles associated with medullary adiposity occurring in patients with anorexia nervosa. the main question it aims to answer is: can this medullary adiposity be associated with the bone deterioration observed in this population? participants will be assessed for body composition and a blood sample will be taken by non-invasive techniques.


Eligibility criteria:
inclusion criteria: for an group: * diagnosis of active an according to dsm-5 criteria * bmi of less than 17kg/m2 * present amenorrhoea in the 3 months prior to the start of the study. for an-r group: * achieved weight gain of more than 85%. * normal menstruation in the last 3 months. for control group: * population of the same age and gender as the an and an-r groups. * if pubertal population, presenting a chronological age of ± 2 years. * normal menstruation * normal bmi (\>18.5 kg/m2) * no presence of previous dietary transtrons. exclusion criteria: * not receiving oestrogens, contraceptives or glucocorticoids in the 3 months prior to the start of the study. * not to suffer from chronic diseases, such as diabetes, pathologies affecting the bone system or thyroid function. * do not take calcium or vitamin supplements.

Keywords: extracellular vesicles bone deterioration biomarkers bone marrow adipose tissue nutritional deficiencies
influence of premedication protocols for neonatal endotracheal intubation on cerebral oxygenation

Conditions: Newborn; Preterm; Intubation

Summary: the purpose of this study is to examine the influence of premedication drugs atropin, fentanyl and mivacurium and of endotracheal intubation on cerebral oxygenation and cardiac output in term and preterm newborn infants. two different protocols of premedication are compared.

influence of the following procedures will be examined: * application of atropin * application of fentanyl * application of mivacurium * possible desaturation and / or bradycardia during intubation attempts * restoration of arterial oxygen saturation and / or heart rate after succesful intubation we aim to examine the change of the following parameters by the use of electrical cardiometry: * stroke volume * cardiac output we compare two different premedication protocols and we evaluate the impact of these protocol on the time needed for intubation and on intubation difficulties .

Eligibility criteria:
inclusion criteria: * newborn infant below 44 weeks postmenstrual age * indication for elective or semi-elective endotracheal intubation * parental informed consent exclusion criteria: * emergency intubation